Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

Journal of Psychopharmacology

Volumn 29, Issue 3, 2015, Pages 289-299

  Bogenschutz, Michael P ^a   Forcehimes, Alyssa A ^a   Pommy, Jessica A ^a   Wilcox, Claire E ^a   Barbosa, PCR ^b   Strassman, Rick J ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b DEPARTAMENTO DE CIÊNCIAS BIOLÓGICAS   (Brazil)

Author keywords

Addiction treatment; alcoholism; clinical trial; hallucinogens; motivational interviewing; psilocybin

Indexed keywords

PSILOCYBINE; PSYCHEDELIC AGENT;

ADULT; ALCOHOL ABSTINENCE; ALCOHOLISM; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRINKING BEHAVIOR; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HUMAN; IRRITABLE COLON; MALE; MOTIVATIONAL INTERVIEWING; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOTHERAPY; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; COGNITIVE THERAPY; EPIDEMIOLOGY; MIDDLE AGED; MOTIVATION; MULTIMODALITY CANCER THERAPY; PREVENTION AND CONTROL; PROCEDURES; TIME; TREATMENT OUTCOME;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HALLUCINOGENS; HUMANS; MALE; MIDDLE AGED; MOTIVATION; PSILOCYBINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84924657991     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114565144     Document Type: Article

References (97)

1. Abuzzahab FS, Anderson BJ. A review of LSD treatment in alcoholism. Int Pharmacopsychiatry. 1971 ; 6: 223-235
2. Akash KG, Anju TR, Peeyush KT, et al. Enhanced dopamine D2 receptor function in hypothalamus and corpus striatum: Their role in liver, plasma and in vitro hepatocyte ALDH regulation in ethanol treated rats. J Biomed Sci. 2008 ; 15: 623-631
3. Akash KG, Balarama KS, Paulose CS. Enhanced 5-Ht(2a) receptor status in the hypothalamus and corpus striatum of ethanol-treated rats. Cell Mol Neurobiol. 2008 ; 28: 1017-1025
4. Anisman H, Du L, Palkovits M, et al. Serotonin receptor subtype and P11 mRNA expression in stress-relevant brain regions of suicide and control subjects. J Psychiatry Neurosci. 2008 ; 33: 131-141
5. Benjamani Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Royal Stat Soc Series B (Method). 1995 ; 57: 289-300
6. Bogenschutz MP. Effects of psilocybin in the treatment of addictions: A review and preliminary results from two ongoing trials. Neuropsychopharmacology. 2012 ; 38: S15 - S16
7. Bogenschutz MP, Pommy JM. Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: From indirect evidence to testable hypotheses. Drug Test Anal. 2012 ; 4: 543-555
8. Bowen WT, Soskin RA, Chotlos JW. Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: A follow-up study. J Nerv Ment Dis. 1970 ; 150: 111-118
9. Buckholtz NS, Zhou DF, Freedman DX, et al. Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain. Neuropsychopharmacology. 1990 ; 3: 137-148
10. Burdick BV, Adinoff B. A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment. Am J Drug Alcohol Abuse. 2013 ; 39: 291-297
11. Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012 ; 109: 2138-2143
12. Carhart-Harris RL, Leech R, Erritzoe D, et al. Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophr Bull. 2013 ; 39: 1343-1351
13. Chwelos N, Blewett DB, Smith CM, et al. Use of D-lysergic acid diethylamide in the treatment of alcoholism. Q J Stud Alcohol. 1959 ; 20: 577-590
14. Cohen J Statistical Power Analysis for the Behavioral Sciences. 1988 ) Statistical Power Analysis for the Behavioral Sciences (2nd Edn). Hillsdale, NJ: Lawrence Erlbaum Associates, Inc. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc ; 1988:
15. Cunningham KA, Anastasio NC. Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction. Neuropharmacology. 2014 ; 76 Pt B: 460-478
16. Diclemente CC, Carbonari JP, Montgomery RP, et al. The Alcohol Abstinence Self-Efficacy Scale. J Stud Alcohol. 1994 ; 55: 141-148
17. Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCS) in humans. Pharmacopsychiatry. 1998 ; 31: 80-84
18. Dyck E. 'Hitting highs at rock bottom': LSD treatment for alcoholism, 1950-1970. Soc Hist Med. 2006 ; 19: 313-329
19. Multidimensional Measurement of Religiousness/Spirituality for Use in Health Research. Kalamazoo, MI: Fetzer Institute ; 1999:
20. First MB, Spitzer RL, Gibbon M, et al Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (Scid-I/P, Version 2.0). New York, NY: Biometrics Research Department, New York State Psychiatric Institute ; 1996:
21. First MB, Spitzer RL, Gibbon M, et al Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition. New York, NY: Biometrics Research Department, New York State Psychiatric Institute ; 1997:
22. Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res. 1999 ; 23: 1289-1295
23. Forcehimes AA. De profundis: Spiritual transformations in Alcoholics Anonymous. J Clin Psychol. 2004 ; 60: 503-517
24. Frokjaer VG, Mortensen EL, Nielsen FA, et al. Frontolimbic serotonin 2a receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol Psychiatry. 2008 ; 63: 569-576
25. Garcia-Romeu AP, Johnson MW, Griffiths RR. Examining the psychological mechanisms of psilocybin-assisted smoking cessation treatment: A pilot study. Abstract book; 2013 San Diego, CA: CPDD conference ; 2013..
26. George AK, Paul J, Kaimal SB, et al. Decreased cerebral cortex and liver 5-HT2a receptor gene expression and enhanced ALDH activity in ethanol-treated rats and hepatocyte cultures. Neurol Res. 2010 ; 32: 510-518
27. Ghitza UE, Zhai H, Wu P, et al. Role of BDNF and GDNF in drug reward and relapse: A review. Neurosci Biobehav Rev. 2010 ; 35: 157-171
28. Gresch PJ, Smith RL, Barrett RJ, et al. Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2a receptor signaling in rat cortex. Neuropsychopharmacology. 2005 ; 30: 1693-1702
29. Griffiths R, Richards W, Johnson M, et al. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008 ; 22: 621-632
30. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011 ; 218: 649-665
31. Griffiths RR, Richards WA, Mccann U, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006 ; 187: 268-283
32. Grinspoon L, Balakar JB Psychedelic Drugs Reconsidered. New York: The Lindesmith Center ; 1997:
33. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011 ; 68: 71-78
34. Grof S LSD Psychotherapy. 2008 ) LSD Psychotherapy. 4 edn.Ben Lomond, CA: Multidisciplinary Association for Psychedelic Studies. Ben Lomond, CA: Multidisciplinary Association for Psychedelic Studies ; 2008:
35. Grof S, Goodman LE, Richards WA, et al. LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry. 1973 ; 8: 129-144
36. Halpern JH. The use of hallucinogens in the treatment of addiction. Addict Res. 1996 ; 4: 177-189
37. Hasler F, Grimberg U, Benz MA, et al. Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl). 2004 ; 172: 145-156
38. Hoffer A The Use of LSD in Psychotherapy and Alcoholism. Abramson HA, ed. Indianapolis: Bobbs-Merrill ; 1967: 343-406.
39. Hollister LE, Shelton J, Krieger G. A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics. Am J Psychiatry. 1969 ; 125: 1352-1357
40. Hood RWJ, Ghorbani N, Watson PJ, et al. Dimensions of the mysticism scale: Confirming the three-factor structure in the United States and Iran. J Sci Study Relig. 2001 ; 40: 691-705
41. James W The Varieties of Religious Experience. Cambridge, MA: Harvard University Press ; 1902:
42. Johnson BA. Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. Biochem Pharmacol. 2008 ; 75: 34-56
43. Johnson BA, Jasinski DR, Galloway GP, et al. Ritanserin in the treatment of alcohol dependence - a multi-center clinical trial. Ritanserin Study Group. Psychopharmacology (Berl). 1996 ; 128: 206-215
44. Johnson MW, Andrew Sewell R, Griffiths RR. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend. 2012 ; 123: 132-140
45. Johnson MW, Garcia-Romeu A, Cosimano MP, et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014 ; 28: 983-992
46. Jones KA, Srivastava DP, Allen JA, et al. Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc Natl Acad Sci U S A. 2009 ; 106: 19575-19580
47. Kast EC LSD: The Consciousness-Expanding Drug. Solomon D, ed. New York, NY: GP Putnam ; 1966: 239-254.
48. Kast EC, Collins VJ. Study of lysergic acid diethylamide as an analgesic agent. Anesth Analg. 1964 ; 43: 285-291
49. Kometer M, Schmidt A, Bachmann R, et al. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry. 2012 ; 72: 898-906
50. Krebs TS, Johansen PO. Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. J Psychopharmacol. 2012 ; 26: 994-1002
51. Kurland AA, Unger S, Shaffer JW, et al. Psychedelic therapy utilizing LSD in the treatment of the alcoholic patient: A preliminary report. Am J Psychiatry. 1967 ; 123: 1202-1209
52. Leuner H The Use of LSD in Psychotherapy and Alcoholism. Abramson HA, ed. Indianapolis: Bobbs-Merrill ; 1967: 101-116.
53. Ludwig A, Levine J, Stark L, et al. A clinical study of LSD treatment in alcoholism. Am J Psychiatry. 1969 ; 126: 59-69
54. Maclean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011 ; 25: 1453-1461
55. Mangini M. Treatment of alcoholism using psychedelic drugs: A review of the program of research. J Psychoactive Drugs. 1998 ; 30: 381-418
56. Martin WR, Sloan JW, Sapira JD, et al. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 1971 ; 12: 245-258
57. Masters R, Houston J The Varieties of Psychedelic Experience: The Classic Guide to the Effects of LSD on the Human Psyche. Rochester, Vermont: Park Street Press ; 2000:
58. Mccrae RR, Costa PT, Martin TA. The Neo-Pi-3: A more readable revised neo personality inventory. J Pers Assess. 2005 ; 84: 261-270
59. Mcnair DM, Lorr M, Droppleman LF Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service ; 1981:
60. Miller WR, C'de Baca J Quantum Change: When Epiphanies and Sudden Insights Transform Ordinary Lives. New York: Guilford Press ; 2001:
61. Miller WR, Rolnick S Motivational Interviewing: Helping People Change. 3rd. ed. New York, NY: Guilford Press ; 2013:
62. Miller WR, Tonigan JS. Assessing drinker's motivation for change: The Stages of Change Readiness and Treatment Eagerness Scale (Socrates). Psychology of Addictive Behaviors. 1996 ; 10: 81-89
63. Miller WR, Tonigan JS, Longabaugh R The Drinker Inventory of Consequences (Drinc): An Instrument for Assessing Adverse Consequences of Alcohol Abuse. Test Manual (Vol. 4). Rockville, MD: US Government Printing Office ; 1995:
64. Morris SB, Deshon RP. Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. Psychological Methods. 2002 ; 7: 105-125
65. Moyers TB, Martin T, Manuel JK, et al. Assessing competence in the use of motivational interviewing. J Subst Abuse Treat. 2005 ; 28: 19-26
66. Nichols DE. Hallucinogens. Pharmacol Ther. 2004 ; 101: 131-181
67. Nichols DE. The Heffter Research Institute: Past and hopeful future. J Psychoactive Drugs. 2014 ; 46: 20-26
68. Pahnke W Drugs and mysticism: An analysis of the relationship between psychedelic drugs and the mystical consciousness. Harvard University ; 1963:
69. Pahnke WN. Psychedelic drugs and mystical experience. Int Psychiatry Clin. 1969 ; 5: 149-162
70. Pahnke WN, Kurland AA, Goodman LE, et al. LSD-assisted psychotherapy with terminal cancer patients. Curr Psychiatr Ther. 1969 ; 9: 144-152
71. Pahnke WN, Kurland AA, Unger S, et al. The experimental use of psychedelic (LSD) psychotherapy. JAMA. 1970 ; 212: 1856-1863
72. Piedmont RL. Does spirituality represent the sixth factor of personality? Spiritual transcendence and the Five-Factor Model. J Person. 1999 ; 67: 985-1013
73. Ray TS. Psychedelics and the human receptorome. PLoS ONE. 2010 ; 5: e9019
74. Richards WA Counseling, peak experiences and the human encounter with death: An empirical study of the efficacy of DPT-assisted counseling in enhancing the quality of life of persons with terminal cancer and their closest family members. Ph.D., Washington, DC: Catholic University of America ; 1975:
75. Richards WA, Rhead JC, Dileo FB, et al. The peak experience variable in DPT-assisted psychotherapy with cancer patients. J Psychedelic Drugs. 1977 ; 9: 1-10
76. Rosell DR, Thompson JL, Slifstein M, et al. Increased serotonin 2a receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patients. Biol Psychiatry. 2010 ; 67: 1154-1162
77. Ross S. Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatric Clin N Am. 2012 ; 35: 357-374
78. Schwartz SH Advances in Experimental Social Psychology. Zanna M, ed. New York: Academic Press ; 1992: 1-65.
79. Schwartz SH. Les valeurs de base de la personne: Théorie, mesures et applications [Basic human values: Theory, measurement, and applications]. Revue française de sociologie. 2006 ; 42: 249-288
80. Shelton RC, Sanders-Bush E, Manier DH, Schwartz SH. Elevated 5-HT2a receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience. 2009 ; 158: 1406-1415
81. Sherwood JN, Stolaroff MJ, Harman WW. The psychedelic experience - a new concept in psychotherapy. J Neuropsychiatr. 1962 ; 4: 69-80
82. Smart RG, Storm T, Baker EF, Schwartz SH. A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior. Q J Stud Alcohol. 1966 ; 27: 469-482
83. Sobell LC, Sobell MB Measuring Alcohol Consumption: Psychosocial and Biological Methods. Litten RA Allen JP, ed. Totowa, NJ: Humana Press ; 1992: 41-72.
84. Sobell LC, Sobell MB Alcohol Timeline Followback Users' Manual. Toronto, Canada: Addiction Research Foundation ; 1995:
85. Soloff PH, Price JC, Meltzer CC, et al. 5HT2a receptor binding is increased in borderline personality disorder. Biol Psychiatry. 2007 ; 62: 580-587
86. Strassman RJ. Adverse reactions to psychedelic drugs. A review of the literature. J Nerv Ment Dis. 1984 ; 172: 577-595
87. Strassman RJ, Qualls CR, Uhlenhuth EH, et al. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry. 1994 ; 51: 98-108
88. Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: The Revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-AR). Br J Addict. 1989 ; 84: 1353-1357
89. Thompson PM, Cruz DA, Olukotun DY, et al. Serotonin receptor, Sert mRNA and correlations with symptoms in males with alcohol dependence and suicide. Acta Psychiatr Scand. 2012 ; 126: 165-174
90. Tomsovic M, Edwards RV. Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: A controlled evaluation. Q J Stud Alcohol. 1970 ; 31: 932-949
91. Tsuchioka M, Takebayashi M, Hisaoka K, et al. Serotonin (5-HT) induces glial cell line-derived neurotrophic factor (GDNF) mRNA expression via the transactivation of fibroblast growth factor receptor 2 (FGFR2) in rat C6 glioma cells. J Neurochem. 2008 ; 106: 244-257
92. Turek IS, Soskin RA, Kurland AA. Methylenedioxyamphetamine (MDA) subjective effects. J Psychedelic Drugs. 1974 ; 6: 7-14
93. Underwood MD, Mann JJ, Huang YY, et al. Family history of alcoholism is associated with lower 5-HT2A receptor binding in the prefrontal cortex. Alcohol Clin Exp Res. 2008 ; 32: 593-599
94. Vaidya VA, Marek GJ, Aghajanian GK, et al. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci. 1997 ; 17: 2785-2795
95. Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nat Rev Neurosci. 2010 ; 11: 642-651
96. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998 ; 9: 3897-3902
97. Wiesbeck GA, Weijers HG, Chick J, et al. Ritanserin in relapse prevention in abstinent alcoholics: Results from a placebo-controlled double-blind international multicenter trial. Ritanserin in Alcoholism Work Group. Alcohol Clin Exp Res. 1999 ; 23: 230-235